INDICATIONS
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
- Previously untreated CD20-positive CLL in combination with FC chemotherapy
- Previously treated CD20-positive CLL in combination with FC chemotherapy
People with serious infections should not receive RITUXAN
IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. The most common side effects of RITUXAN in patients with chronic lymphocytic leukemia were infusion reactions and low white blood cells. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.
Please see full Prescribing Information, including the Medication Guide.
Rituxan® and its logo are trademarks of Biogen Idec, Inc.
The Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.
Health Care Professional
Genentech Access Solutions can assist in managing the patients you refer to us. However, the use of our forms and the accuracy of the information provided are your responsibility and not that of Genentech Access Solutions.
Patient / Caregiver
Genentech Access Solutions can help you in getting the medicine you need. However, it is up to your doctor's office to provide accurate information when filling out our forms.
/Logo_Biogen.jpg){kind=logo}